Alzheimer's Disease Competitive Intelligence: March 15, 2026

Mar 1, 2026 – Mar 15, 2026

The first two weeks of March 2026 marked meaningful progress across the neurodegeneration pipeline, with four clinical-stage companies advancing programs in Alzheimer's disease and related dementias. Cognition Therapeutics secured FDA alignment on a registrational pathway for zervimesine in dementia with Lewy bodies (DLB) psychosis — an indication with no approved therapies where many standard antipsychotics are contraindicated. CervoMed resolved a critical manufacturing challenge for neflamapimod, locking in a 50mg TID stable crystal formulation for its planned Phase 3 DLB trial. Passage Bio reported dual enrollment milestones in the upliFT-D gene therapy study for genetic frontotemporal dementia. Voyager Therapeutics outlined a 2026 clinical entry plan for two tau-targeting assets in Alzheimer's disease: VY1706, a tau-silencing gene therapy targeting IND submission in Q2, and VY7523, an anti-tau antibody with MAD trial enrollment complete and tau PET data expected in H2 2026.